Overview of Nanofib

Property	Description
Active ingredient	Fenofibrate
Form	Oral preparation (solid dosage form)
Pharmacological class	Fibrate (Fibric Acid Derivative)
General purpose	Management of high blood fat levels
Origin	Synthetic organic compound

What Type of Medicine is Nanofib (Fenofibrate)?

Nanofib is a prescription-only medication containing the active ingredient Fenofibrate, a synthetic organic compound classified as a fibrate or fibric acid derivative. This single-active ingredient product is fundamentally categorized as an antihyperlipidemic agent, a type of medicine used to manage abnormalities in circulating blood fats. Fenofibrate is clinically recognized for its essential function as a Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha) Agonist, placing it within a specialized group of agents that regulate lipoprotein metabolism.

As a monotherapy preparation, Fenofibrate is distinguished by its primary role in helping to correct dyslipidemia, which is the general medical term for an unhealthy balance of fats in the bloodstream. This identity confirms the drug's purpose is focused on systemic regulation of blood lipids rather than solely inhibiting cholesterol synthesis.

What Is the Nanotechnology Formulation of Nanofib?

Nanofib is an oral preparation provided as a solid dosage form, typically a capsule or tablet. A key feature is its utilization of advanced nanotechnology formulation (or micronization technology), which creates nanomized particles of the Fenofibrate active ingredient. This particle size reduction is a specialized aspect of the formulation.

This unique nanotechnology formulation is employed because Fenofibrate naturally exhibits low water solubility. The increased surface area achieved through micronization technology ensures significantly enhanced dissolution and absorption. This leads to modified pharmacokinetics, ensuring the drug is consistently and efficiently available to exert its intended therapeutic effect.

What is the General Purpose of Fenofibrate?

The general purpose of Fenofibrate is to restore balance to abnormal lipid profiles, often generalized as hyperlipidemia or mixed dyslipidemia. The medication achieves this through its unique physiological action as a PPARalpha activator. This mechanism is known to lead to two primary benefits: significant triglyceride reduction and notable HDL cholesterol elevation.

This dual effect on lipoprotein metabolism makes the medicine suitable for patients whose lipid imbalance requires targeted clearance of circulating fat particles and enhancement of beneficial lipid transport. The antihyperlipidemic agent function provides a potent foundational benefit in regulating high levels of circulating fats.

Regulatory References

What side effects are possible with Nanofib?

Possible Side Effects and Safety Information: Nanofib

The safety profile of Fenofibrate, the active ingredient in Nanofib, is defined by regulatory agencies based on frequency and affected body systems. These classifications guide the required monitoring and establish constraints for use.

Documented Adverse Reactions

Side effects are formally grouped by the system-organ class (SOC) affected. The primary areas of concern documented in official labeling include Hepatobiliary Disorders (liver and gallbladder), Musculoskeletal and Connective Tissue Disorders (muscles), and the Gastrointestinal System.

Frequency Classification	Examples of Reactions
Common (up to 1 in 10)	Elevated liver enzymes (transaminases), abdominal pain, nausea.
Uncommon (up to 1 in 100)	Pancreatitis, cholelithiasis (gallstones), muscle disorders (myalgia, myositis), venous thromboembolic events.
Rare (up to 1 in 1,000)	Rhabdomyolysis, hepatitis, serious cutaneous adverse reactions (SCARs), alopecia.

Serious Safety Considerations and Restrictions

Official prescribing information highlights the risk of serious adverse reactions, including Rhabdomyolysis and Venous Thromboembolism (DVT and Pulmonary Embolism). These are rare but clinically significant events that warrant strict adherence to regulatory guidelines.

Use of Fenofibrate is contraindicated by government mandate in patients with pre-existing severe conditions, including severe hepatic impairment (liver dysfunction), severe renal impairment (kidney dysfunction), and pre-existing gallbladder disease. Furthermore, muscle symptoms, such as myalgia, may be observed more frequently early in the course of treatment or during dose escalation. Regulatory guidance requires regular monitoring of liver and renal function throughout treatment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory guidance mandates seeking immediate medical attention upon known or suspected overdose of Nanofib (Fenofibrate). This instruction applies regardless of whether specific symptoms are currently present.

Documented Presentations and Required Action

The documented profile indicates that overdose presentations are often asymptomatic, though non-specific symptoms such as gastrointestinal effects (e.g., nausea or diarrhea) may occur. Overdose is generally not associated with unique, life-threatening toxicity. Urgent emergency services must be contacted if severe, non-specific signs are observed, including collapse, seizure, trouble breathing, or unconsciousness.

Official Management Strategy

The regulatory framework states clearly that no specific antidote is known for Fenofibrate overdose. Management is therefore limited to general symptomatic and supportive treatment. This includes the required monitoring of vital signs and clinical status by medical personnel. In cases of recent ingestion, procedures such as gastric lavage may be considered to limit further absorption. Furthermore, due to the drug’s extensive binding to plasma proteins, hemodialysis is not considered an effective measure for drug removal.

Therapeutic Uses of Nanofib

What Nanofib Treats: Main Uses and Benefits

Nanofib is generally used in situations involving certain distressing symptoms related to systemic imbalance in circulating fats, serving as part of symptomatic management for blood fat abnormalities. It is commonly used in combination with diet and exercise when these lifestyle efforts are insufficient. The core therapeutic domains is considered relevant for the management of mixed dyslipidemia, primary hypercholesterolemia, and severe hypertriglyceridemia.

This medication is commonly used across conditions presenting with elevated measured blood fats, and helps address symptom clusters related to high triglycerides and low HDL cholesterol. In cases of very high triglycerides (≥ 500 mg/dL), Nanofib is considered relevant because this therapeutic domain contributes to easing the overall symptom load in conditions where symptoms create noticeable physiological strain due to triglyceride concentration.

Nanofib may be part of symptomatic management in high-risk patients, such as those with Type 2 Diabetes Mellitus, when lipid abnormalities persist despite other therapies.

Quick Fact: Support for Systemic Imbalance Nanofib plays a role in managing the measured abnormality of high triglycerides and low HDL cholesterol, and is applied when appropriate to help support general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nanofib?

Nanofib (Fenofibrate) is officially designated for use only by adult patients. Eligibility for this medicine is determined by strict non-eligibility rules established in regulatory documents, which focus on organ function and specific comorbidities.

Absolute Contraindications (Must Not Use)

Use of Nanofib is contraindicated and absolutely prohibited for several populations, including patients with severe renal impairment (eGFR below 30 mL/min/1.73m^2), active liver disease (such as primary biliary cirrhosis), or pre-existing gallbladder disease. It is also contraindicated in nursing mothers and those with a known hypersensitivity to fenofibrate or other fibrates.

Restricted and Conditional Use

For patients with mild to moderate renal impairment (eGFR 30 - 59 mL/min/1.73m^2), use is permitted only with a mandatory dose reduction and close monitoring. Use is not recommended for the pediatric population (under 18 years of age) because safety and efficacy are not established. For pregnant women, use is conditional and only permitted if the potential benefit justifies the potential risk. Underlying causes of high blood fats, like uncontrolled hypothyroidism, must be treated prior to initiating this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nanofib’s regulatory profile documents several classes of medicinal products that require administration constraints due to documented interaction patterns. The resulting interaction structure is defined by both pharmacodynamic effects and specific timing rules.

Pharmacodynamic Risk of Enhanced Myotoxicity

Co-administration with HMG-CoA Reductase Inhibitors (Statins) and Colchicine carries a pharmacodynamic interaction risk that increases the potential for serious muscle toxicity, including myopathy and rhabdomyolysis. Regulatory documents state that the combined use with statins should be avoided unless the anticipated benefit outweighs this heightened risk. This additive risk is officially noted as being greater in populations such as elderly patients and those with underlying conditions like renal failure or hypothyroidism.

Pharmacokinetic and Absorption Constraints

The profile dictates strict timing requirements for certain agents. Bile Acid Binding Resins must be administered at least one hour before or four to six hours after Nanofib to prevent the physical binding that reduces Nanofib's absorption and systemic exposure. Fenofibric acid is also documented as a mild-to-moderate inhibitor of the CYP2C9 enzyme, a pharmacokinetic interaction that can increase the systemic exposure of other co-administered drugs metabolized by this pathway, such as Glimepiride.

Other Clinically Significant Interactions

Co-administration with Oral Coumarin Anticoagulants requires caution, as Nanofib enhances the anticoagulant effect, which formally necessitates an adjustment to the anticoagulant's dosage. Use with Immunosuppressants (e.g., Cyclosporine) is noted for an increased risk of nephrotoxicity due to the drug’s reliance on renal excretion. Furthermore, the specialized formulation of Nanofib is specified to be taken with food to achieve optimal absorption.

Mechanism of Action

How Nanofib Works: Mechanism of Action

Activating the Nuclear Receptor and Gene Modulation

The drug's active form (Fenofibric acid) works by acting as an agonist for the PPAR alpha (Peroxisome Proliferator-Activated Receptor Alpha) nuclear receptor. This primary molecular interaction allows the receptor complex to bind to DNA, which then modulates the expression of genes that control lipid and lipoprotein metabolism. This genomic action initiates the entire mechanistic cascade.

Enhancing Fat Clearance (Lipoprotein Catabolism)

Gene modulation triggered by PPAR alpha activation significantly increases the production of Lipoprotein Lipase (LPL) and simultaneously decreases its inhibitor, Apolipoprotein C-III (ApoC-III). This synergy enhances the lipolysis (breakdown) and removal of fat-rich particles, such as triglycerides in VLDL, from the bloodstream. This leads directly to the physiological consequence of enhanced catabolism of circulating triglycerides.

Remodeling Cholesterol Carriers

The drug's mechanism also increases the production of Apolipoprotein A-I/A-II, which are essential components of HDL (High-Density Lipoprotein). This action results in the formation of ApoA-I/A-II, which facilitates cholesterol efflux from peripheral tissues, and alters the composition of LDL particles.

Dosage and Administration Information

How to Use Nanofib

Nanofib is strictly administered orally as a single dose once daily. The solid dosage form, whether a tablet or capsule, must be swallowed whole and must not be crushed, broken, or chewed to preserve the intended absorption characteristics of the micronized formulation.

Standard Dosing Regimens and Timing

Adult dosing for primary hypercholesterolemia or mixed dyslipidemia typically ranges from 105 mg to 160 mg once daily, depending on the specific product formulation. For patients with severe hypertriglyceridemia, the initial dose may range from 35 mg to 145 mg daily. The requirement to take the medicine with a meal is formulation-dependent and must be confirmed by the specific product label.

Procedural Course and Adjustments

The course of treatment is structured by official protocols: lipid levels must be assessed at intervals of four to eight weeks after starting or adjusting the dose. Treatment is officially instructed to be discontinued if a satisfactory therapeutic response is not achieved after two months of therapy at the maximum approved dosage.

Population-Specific Dose Rules

Dosing must be modified for patients with mild to moderate renal impairment, requiring a lower starting dose (e.g., 35 mg to 48 mg once daily). Use in patients with severe renal impairment (eGFR < 30 mL/min/1.73m²) is generally avoided. Dose selection for older adults must also be based on an assessment of renal function. The use of Fenofibrate in the pediatric population is not established, and it is not routinely recommended.

Recent Clinical Evidence

Research evidence / Overview of studies for Nanofib

Evidence for Use in Primary and Mixed High Blood Fat Levels

The research evaluated Fenofibrate in contexts exploring conditions associated with high levels of blood fats, known as dyslipidemia, including primary hypercholesterolemia and mixed dyslipidemia. Researchers conducted various short-term Randomized Controlled Trials (RCTs) and comparative studies to examine how Fenofibrate was associated with shifts in lipid biomarkers, such as Triglycerides (TG) and HDL cholesterol.

In these short-term studies, research describes changes measured during the study period in the observed populations. Specifically, studies reported patterns where Triglyceride concentrations and HDL cholesterol concentrations were measured from the starting point. The current body of research on this clinical situation is primarily based on evidence derived from studies focusing on the quantitative shift in lipid biomarkers.

Evidence for Use in Managing Severe Hypertriglyceridemia

Nanofib was also evaluated in adult populations presenting with severe hypertriglyceridemia, defined as having exceptionally high levels of Triglycerides (often 500 mg/dL or greater). Research evaluated Fenofibrate in the context of measured changes in the concentration of Triglycerides.

Short-term controlled clinical trials reported observed patterns of Triglyceride level measurements across the examined high-risk populations. Evidence is limited regarding the long-term observation of this reduction, and the data are still emerging. Data related to any potential association with the frequency of acute pancreatitis remains insufficient.

Studies in Patients with Type 2 Diabetes and Related Conditions

Fenofibrate was observed in large-scale, long-term Randomized Controlled Trials (RCTs), such as FIELD and ACCORD Lipid, involving adult patients with Type 2 Diabetes Mellitus (T2DM). For the overall T2DM population studied, research reported that no difference in the rate of the primary composite outcome of major cardiovascular events was observed between the Fenofibrate group and the control group.

Observations Regarding Microvascular Outcomes

Secondary analyses from these same long-term trials examined Fenofibrate's association with complications related to T2DM. Research described observations related to diabetic retinopathy measurements. Specifically, studies monitored and reported the measured frequency of the need for laser treatment for retinopathy.

Key Studies & References NIH MedlinePlus: Fenofibrate (Oral)

Frequently Asked Questions (FAQ)

Common questions about Nanofib (FAQ)

Q: How is Nanofib different from older medicines used for the same condition?

A: Nanofib is a type of medicine called a fibrate, which works differently than other drugs like statins, even though they treat similar conditions. The official product information notes that the formulation uses micronization technology to enhance the absorption of the active ingredient, Fenofibrate. This specialized formulation is used to achieve enhanced absorption of the active ingredient, Fenofibrate.

Q: Do you have to take Nanofib forever, or is it a short-term treatment?

A: Regulatory information indicates that treatment is discontinued if a satisfactory improvement in blood fat levels is not observed after two months of therapy at the maximum approved dosage. While this instruction handles cases where the drug isn't effective, the product labeling does not specify the typical duration of treatment for patients who do respond well. The long-term course of treatment requires ongoing clinical assessment.

Q: Is there a generic version of Nanofib available yet?

A: The active ingredient in Nanofib, Fenofibrate, is widely available in many generic forms and formulations. Nanofib uses a specialized formulation (micronization) which enhances its absorption. Confirmation of an exact generic equivalent to this specific Nanofib formulation is obtained through a healthcare provider.

Q: Can Nanofib interact with vitamins or herbal supplements?

A: Official labeling details specific interactions with prescription medicines like blood thinners and statins. While interactions with every vitamin or herbal supplement are not typically listed, the product information does note that Fenofibrate can cause a decrease in Vitamin B12 levels. Fenofibrate's use in conjunction with all other medicines, supplements, or herbs requires disclosure to a healthcare provider for a risk assessment.

Q: Is Nanofib safe for women who are trying to conceive?

A: Regulatory documents state that use during pregnancy is considered conditional, meaning it's permitted only if the potential benefit justifies any potential risk to the fetus. There is no specific regulatory guidance regarding the period before conception. A decision regarding the use of this medication when planning a pregnancy requires individual risk and benefit assessment.

Q: What are the early signs that Nanofib is working?

A: The effectiveness of Nanofib is measured objectively by assessing your blood fat levels, specifically triglycerides and HDL cholesterol, which is typically done every four to eight weeks after starting or adjusting the dose. The official product labeling does not detail any subjective or patient-perceived signs of efficacy that are expected early in the course of therapy.

Q: How long until I start feeling the effects of Nanofib?

A: The therapeutic effects of Nanofib on your blood fat levels are officially monitored by lab tests, which are usually conducted as early as four to eight weeks after beginning treatment. The product information does not specify a timeframe for when a person may feel any subjective change, as the drug primarily works to change blood lipid levels.

Q: Do you need a special diet while taking Nanofib?

A: Yes, regulatory guidance specifies that a lipid-lowering diet should be established before starting Nanofib, and adherence to this diet is expected throughout the course of treatment. Additionally, the specific formulation of Nanofib is instructed to be taken with food to ensure optimal absorption into the body.

Q: What happens if you miss a dose of Nanofib?

A: According to the patient counseling information, if a dose is missed, the regulatory guidance states that an extra dose should not be taken. Treatment is resumed by taking the next scheduled dose at the regular time.

Q: Is Nanofib approved for use in children?

A: The official product labeling indicates that the safety and effectiveness of Fenofibrate in children and adolescents under 18 years of age has not been established. Therefore, the use of Nanofib is not recommended for the pediatric population.

Q: Can taking Nanofib cause sensitivity to sunlight?

A: Yes, regulatory documents note that Nanofib is contraindicated (prohibited) in people with a known history of photoallergy or phototoxic reactions to other similar medicines. Postmarketing reports have also included instances of photosensitivity reactions while using this drug.

Q: Does Nanofib make you tired during the day?

A: Routine daytime tiredness or fatigue is not listed as a common side effect in the official product information for Nanofib. However, the regulatory labeling does note that general fatigue and unusual weakness can be potential symptoms of rare, serious muscle-related side effects, and are conditions that require prompt disclosure to a healthcare provider.

Q: How quickly is Nanofib absorbed into the system?

A: Fenofibrate is rapidly broken down in the body into its active form (fenofibric acid) after an oral dose. The highest concentration of the active ingredient in the blood is typically reached in approximately 6 to 8 hours after administration.

Q: What kind of studies support the use of Nanofib in young adults?

A: Clinical studies are conducted on the broader adult population. However, pharmacokinetic studies, which track how the drug moves through the body, have compared young adults to older patients and found that the rate at which fenofibric acid is cleared from the body is similar between these groups.

Q: What are the long-term effects of taking Nanofib?

A: Long-term randomized controlled trials have been performed, primarily focusing on patients with Type 2 Diabetes Mellitus. These studies focused on major cardiovascular outcomes and did not show a difference between the Nanofib group and the control group for these events. For safety, continued therapy requires periodic monitoring of liver and renal function as documented in regulatory warnings.

Q: Does Nanofib require any special monitoring or blood tests?

A: Yes, periodic monitoring is required throughout the course of treatment. Official warnings state that liver function tests and renal (kidney) function must be monitored regularly. Periodic blood counts are also recommended, especially during the first year of treatment.

Q: Can Nanofib interfere with common lab test results?

A: Official labeling documents that Nanofib can potentially affect certain lab test results. These effects include temporary increases in serum creatinine (kidney function marker) and increases in serum transaminases (liver enzymes). Mild decreases in blood cell counts have also been observed.

Q: Is Nanofib considered a high-risk medication?

A: Nanofib is contraindicated (prohibited) in patients with specific severe conditions, such as severe liver or kidney impairment. It also carries warnings about the potential for serious, though rare, adverse reactions, including severe muscle toxicity (rhabdomyolysis) and venous thromboembolism (blood clots).

Q: Can Nanofib be taken if you have a history of stomach issues?

A: Nanofib is strictly contraindicated for patients with pre-existing gallbladder disease or active liver disease. While common gastrointestinal side effects like abdominal pain and nausea are known, use in patients with other non-liver/gallbladder stomach issues is a determination made through medical evaluation.

Q: How long after taking Nanofib is the concentration highest in the blood?

A: The highest concentration of the active ingredient (fenofibric acid) in the bloodstream, known as the peak plasma concentration, is typically reached approximately 6 to 8 hours after the oral dose is taken.

Q: Is the Nanofib dose the same for everyone?

A: No, the dose is individualized and not the same for everyone. The dosage is determined by the patient's response and must be modified for those with mild to moderate renal (kidney) impairment. The selection of a safe starting dose is based on an individual assessment by a healthcare provider.

Q: Are there any specific warning signs to look out for while on Nanofib?

A: Yes, regulatory guidance highlights the importance of promptly disclosing any unexplained muscle pain, tenderness, or weakness, especially if it occurs with fever or malaise, as these can be signs of serious muscle issues. Signs of potential liver problems, such as jaundice (yellowing of the skin or eyes), also require immediate disclosure to a healthcare provider.

How should Nanofib be stored and disposed of?

How to Store and Dispose of Nanofib

The storage of Nanofib (Fenofibrate) must adhere strictly to controlled room temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medication must be protected from moisture and should not be stored in areas with excessive humidity. It is required to keep Nanofib in its original container and ensure the bottle is tightly closed to maintain product stability.

Stability and Safety

If supplied in a bottle, the product is stable for 6 months after the initial opening. To ensure child safety, the medicine must be stored out of the reach and sight of children.

Disposal

Unused or expired Nanofib must be disposed of according to local, state, or federal regulations. It is explicitly prohibited to flush this medication down a toilet or pour it into a drain.

Nanofib